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The antibiogram is an essential resource for institutions to track changes in antimicrobial resistance and to guide
empirical antimicrobial therapy. In this Viewpoint, data and examples from literature are presented that suggest
institutions have not completely adopted the standardized approach in developing antibiograms, as variations in
the development methodologies of antibiograms exist despite consensus guidelines (M39) published by CLSI.
We emphasize developing antibiograms in line with the M39 recommendations will help ensure that they are ac-
curate, reliable and valid, and highlight that understanding the limitations of antibiogram data is critical to
ensuring appropriate interpretation and application to clinical decision-making. We also stress the importance of
easy accessibility and education on antibiogram use, to allow for prescribers to select the most optimal empirical
treatment regimens and propose the creation of an abbreviated antibiogram for frontline users. Multidisciplinary
antimicrobial stewardship programmes are vital to accomplishing these goals.
Considerations in antibiogram development
and reporting
The cumulative antibiogram is a periodic profile of antimicrobial
susceptibilities of various organisms isolated from patients within
an institution or can be developed to track patterns of resistance in
broader geographic areas using data from multiple institutions. It
is commonly utilized to monitor recent antimicrobial susceptibility
patterns in order to guide empirical antimicrobial therapy selec-
tion.1 Components of the cumulative antibiogram include organ-
ism names, number of isolates analysed, antimicrobial agents
tested and the percentage of each organism interpreted as
susceptible to listed antimicrobial agents based on the CLSI rec-
ommended breakpoints.2,3 While antibiograms have been com-
monly utilized by institutions over the past decades, there are
variations in the development methodologies of cumulative anti-
biograms. Additionally, determination of susceptibility rates may
be based on flawed calculation methodologies.4 Contributions to
flawed susceptibility calculations can include delayed adoption of
the most up-to-date CLSI breakpoints and use of FDA or EUCAST
breakpoints.5–8 CLSI updates with lowered breakpoints have been
shown to increase the resistance rates of specific organisms.9
Breakpoint changes and implementation remained a challenge for
all laboratories, as not all automated susceptibility testing systems
have FDA clearance for the revised (current) breakpoints.
Additionally, the challenge is compounded by the need for labora-
tories to perform validation studies.10 Delaying or not updating
to the most recent CLSI breakpoint recommendations would in-
flate antimicrobial percentage susceptibility. The inconsistencies
among institutions in the preparation of cumulative antibiograms
led to the development of CLSI consensus guidelines. Therefore,
the M39 guidance document for the development and implemen-
tation of cumulative antibiograms in healthcare facilities was
first published in 2006.4 This guideline was created to provide
standardized guidance to institutional laboratories on antibiogram
development to ensure accuracy, reliability and statistical validity.
Of note, M39, as with all guidelines, is not mandatory for institu-
tions to adhere to and is only a recommendation, despite being
critical during this era of antimicrobial resistance.
The M39 guideline provides specific recommendations for
the collection, storage, analysis and presentation of data and
includes example templates showcasing the recommendations.
In 2014, CLSI published an update to the M39 guideline. The
update included further guidance on the preparation and use of
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cumulative antibiogram reports, and recommendations on the de-
sign and support of the clinical laboratory’s susceptibility data
management needs.4 Additionally, CLSI identified modalities of
antibiogram presentation to enhance its usefulness, including
stratification of susceptibility data by body site (e.g. urine and non-
urine isolates), hospital unit (e.g. ICU, emergency department
[ED]) and/or specific patient populations. Other components
added to the antibiogram have been described, such as drug cost,
dosing guides and drug-use policies.2 Thus, the preparation,
reporting and utilization of the antibiogram can be customized to
meet the needs of each institution.
It is imperative for institutions to ensure M39 guidance recom-
mendations are adopted to ensure accuracy and quality, as anti-
biograms are frequently used within institutions for formulary
decisions, development of hospital treatment guidelines and order
sets, monitoring resistance trends and empirical antimicrobial
therapy recommendations. Several distinct approaches can be
used in generating cumulative antimicrobial susceptibility testing
(AST) reports from a microbiology laboratory database. These
approaches include manual data collection or the use of analytical
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are capable of generating rolling antibiograms,
based on specific dates that are input, thus providing the ability to
create an antibiogram based on a specific timeframe. No studies
have reported whether any of the above approaches is more ad-
vantageous than another, particularly if all analytical surveillance
system data have been validated. However, data generation and
analysis are less time consuming when utilizing analytical surveil-
lance software. Additionally, it will likely provide a platform for
more robust analysis including additional data stratification via lo-
cation and/or infectious syndromes. M39 also provides guidance
on the validation process for data analysis and calculation.3 A
checklist is provided in M39 and should be used as a quality assur-
ance check to ensure that the analytical surveillance software uti-
lized calculates the data accurately and selection criteria are met.
For example, in order to validate the data analysis output, results
generated from one system (e.g. laboratory platform) should be
compared with results generated from another system (e.g. the
antimicrobial susceptibility instrument), provided both systems
use the same calculation algorithms. Finally, M39 recommends
that all antimicrobials routinely tested be included in the antibio-
gram susceptibility analysis even if they are suppressed by cascad-
ing rules. Institutions must be vigilant that datasets used for
analysis contain all results, including those suppressed, as exclud-
ing these results will lead to biased susceptibility for the secondary
agents that are released when cascading rules are met.3 Thus, a
potential pitfall in producing an EHR-based antibiogram is the
skewed susceptibility results unless whole unsuppressed data are
released from the automated AST platforms.
Despite the release of M39 over a decade ago, there is consider-
able variation in the analysis and presentation of cumulative AST
data among institutions.2,11 Several nationwide surveys have
reported the adoption rate of the M39 recommendations to range
from 47% to 60%.2,12,13 Ernst et al.12 examined the adherence of
American acute care hospitals, of which 40% were teaching
hospitals and most exceeded 200 beds, to the National
Committee for Clinical Laboratory Standards (the former name of
CLSI) guideline published in 2002. It was found that only 60% of
institutions met guideline criteria for the antibiogram compilation,
which included annual updating and distribution to infection con-
trol and medical staff yearly. A survey in 2006 also found substan-
tial variability in the development and reporting of institutional
antibiograms across the United States and found that academic
hospitals and hospitals with greater number of personnel were sig-
nificantly more likely to develop more sophisticated and advanced
variations of the antibiogram in addition to the cumulative antibio-
gram.13 In a later study, Xu et al.2 evaluated hospital policies in re-
gard to the generation, reporting and utilization of antibiograms
among 47 hospital laboratories. They found nearly all (98%) of lab-
oratories generated annual antibiograms, but only 47% reported
that they had adopted all of the standards recommended by CLSI.
The authors also found that, when examining which M39 guideline
criteria hospital laboratories were adhering to, only 64% of sur-
veyed laboratories required at least 30 isolates for each reported
species, which was the lowest adhered to of the key M39 recom-
mendations. The lack of adherence to this M39 recommendation
was also observed in a study conducted by Moehring et al.:14 only
25% of hospital laboratories followed this recommendation, and
only 3% of laboratories where less than 30 isolates were reported
included footnotes stating the reduced statistical validity with
such low isolate numbers. The importance of denoting organisms
and susceptibility results without the minimum 30 isolates corre-
lates to the statistical validity of the percentage susceptibility rep-
resented in the antibiogram. Using a smaller sample size will result
in a wider 95% CI. The 95% CI for 80% susceptibility with a sample
size of 30 is 0.623 to 0.909, whereas a sample size of 10 would pro-
vide a 95% CI ranging from 0.479 to 0.954, leading to a diminished
predictive value of antibiograms when using smaller samples sizes.
Subsequently, only 3% of the 37 surveyed laboratories produced
antibiograms in complete compliance with CLSI guidelines, while
47% of laboratories in the Xu et al.2 study reported full compli-
ance.14 Based on the studies described above, it is apparent
that not all hospital laboratories follow the CLSI M39 guideline in
its entirety; though it was found that the majority of institutions
did create annual cumulative antibiograms. As CLSI routinely
updates the M39 document, with an update currently being devel-
oped, the current recommendations for antibiogram development
will change and more institutions will need to adopt a new set of
standards.
Once an institution develops an accurate and reliable cumula-
tive antibiogram that adheres to M39 recommendations, institu-
tions should consider exploring the generation of an enhanced
antibiogram. Several studies have evaluated different approaches
to enhanced antibiogram reporting to improve the functionality of
the traditional cumulative antibiogram.15–19 One approach is
reporting location-specific susceptibilities since institution-wide
cumulative antibiograms may mask important differences in sus-
ceptibility rates. Kaufman et al.16 reported that the susceptibilities
of Staphylococcus aureus and Pseudomonas aeruginosa isolated
in a single surgical ICU unit were significantly lower than those
reported in the institution-wide antibiogram. Several studies eval-
uated alternative antibiogram presentation strategies such as by
infection site and patient disposition in addition to location.18,19
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result in diminished sample size and possibly less than the 30 iso-
late threshold. Potential solutions would be to combine organisms
into larger groups (e.g. Enterobacterales) or include multiple years,
as this would increase the sample size considerably. Jorgensen
et al.18 evaluated their institution’s ED-specific antibiogram sus-
ceptibility patterns by patient characteristics including gender,
age, residence prior to admission and disposition. Their study
revealed distinct differences in urinary Escherichia coli susceptibility
as a function of patient characteristics. Lower ampicillin and gen-
tamicin susceptibilities were seen in females aged 18 to 50 years in
comparison to females aged 50 years or older. Lower trimetho-
prim/sulfamethoxazole susceptibilities were seen in patients
65 years old or younger versus those greater than 65 years of age.
Hence, antibiograms stratified by patient characteristics may bet-
ter guide empirical antibiotic selection for urinary tract infec-
tions,18,19 highlighting the need to tailor antibiograms to match
specific patient populations. In another example, Pogue et al.17
evaluated unit-specific traditional versus combination antibio-
grams incorporating all ICU Gram-negative isolates recovered
from respiratory cultures in order to improve optimal empirical
antimicrobial selection in pneumonia. The authors found that the
combination of cefepime and tobramycin was the most optimal
empirical Gram-negative regimen in ICU patients with a suspected
pulmonary source. Generating pathogen susceptibility data strati-
fied by infection syndrome may provide prescribers a streamlined
approach to empirical therapy selection for a specific infectious
process such as pneumonia.17
Limitations of antibiogram applicability
A traditional cumulative antibiogram has potential limitations that
may hinder its general applicability. For example, it does not reveal
the timing of isolate collection relative to a patient’s hospital
admission. Hence, it cannot reliably distinguish between a com-
munity-acquired versus hospital-acquired infection.1 Institutions
may consider developing an antibiogram based on timing of
culture collection relative to patient admission. A standard defin-
ition of 48 h as the pivotal point can be utilized, in which ,48 h is
classified as community onset and 48 h as hospital onset.20,21
This stratification may offer a more accurate analysis of hospital
versus community susceptibility rates and potentially lead to bet-
ter representation of community versus hospital organism ecol-
ogy, resulting in improved empirical therapy recommendations.
Limitations to this approach exist however, such as situations in
which cultures are obtained more than 48 h after admission
despite the infectious onset being in the community, which can
lead to community-onset infections being categorized as hospital-
onset infections. Likewise, as a limitation, a colonizing organism al-
ready present on a patient, which later causes an infection after
admission may be categorized as hospital-acquired. Additionally,
the practicality of collecting information needed to determine
community versus hospital onset could be labour intensive and
individual chart reviews may be required when sophisticated
technological means are not available. Another intrinsic limitation
is that a traditional antibiogram does not differentiate between an
organism that is isolated from a patient as a pathogen versus col-
onizer. The inclusion of colonizing organisms in the percentage
susceptibility calculation may influence susceptibility rates.4
Antibiograms provide binary measures of susceptibility
(whether a pathogen is non-susceptible or susceptible) but do not
provide quantitative data, such as MIC or further categorization of
non-susceptibility into intermediate or resistant.1 Granular data
such as MIC distributions that are below the clinical breakpoint are
not reported on antibiograms. Thus, information regarding MICs at
or near the breakpoint will not be apparent. For example, vanco-
mycin MIC distributions at 2 mg/L have been shown to adversely
influence treatment outcomes in invasive MRSA infections despite
being within the susceptible range.22 Nevertheless, reporting
MIC data or adding further categorization of non-susceptibility on
an antibiogram may lead to difficulty in interpretation and use.
However, one particularly helpful example of including MIC distri-
bution is with Enterobacter cloacae and cefepime susceptibilities.
Here, the organism MIC values dictate susceptibility classification
such as susceptible and susceptible dose dependent (SDD).
This classification is coupled with an alternative cefepime dosing
scheme to maximize drug exposure. For example, if the organism
is categorized as cefepime SDD, then maximal doses are recom-
mended to optimize the probability of pharmacodynamic attain-
ment (i.e. MIC"8 mg/L, cefepime 2 g every 8 h). When cefepime
is selected empirically to cover E. cloacae, information on the
percentage of isolates that are SDD may prove meaningful.
While antibiograms are useful, they cannot be relied upon as
the sole resource for guiding empirical antimicrobial therapy. Static
antibiograms may have limited use in selecting empirical therapy
in patients with recurrent or recent infections, as the patient’s
microbiological history and prior antibiotic use may provide more
useful information during therapy selection. Additionally, pharma-
cotherapeutic factors such as site of infection, antimicrobial
pharmacokinetic/pharmacodynamic properties, contraindications,
organism selective pressures and collateral damage, Clostridioides
difficile infection risk and efficacy/safety data are all critical consid-
erations in conjunction with antibiogram susceptibility informa-
tion. More sophisticated antibiograms are on the horizon by way of
machine learning to model individual patient data from the EHR to
create a personalized antibiogram.23 Modelling personalized anti-
biograms maybe possible in the near future, but requires validation
and inclusion of variables that are not available in the EHR such
as antimicrobial history of infectious contacts.
Optimal antibiogram utilization
When an antibiogram is used for empirical antimicrobial therapy
selection, its application can be more precise when the infecting
organism is identified prior to susceptibility results. It is less precise
when the infecting organism is not known but is suspected based
on the site and/or type of infection. Since antibiograms provide
prescribers a resource in the selection of an empirical antimicrobial
regimen, it is critical that the antibiogram is a practical and user-
friendly resource. Institutions can create a practical abbreviated
antibiogram, in addition to the standard cumulative antibiogram
and its variations. An example of a practical abbreviated antibio-
gram is one that lists relevant organisms most commonly encoun-
tered in typical infections along with the common antibiotics used
to treat these infections (Figure 1). For example, E. coli and
Citrobacter freundii likely would have .30 isolate occurrences with-
in a year; however, E. coli would be considered a more relevant or-
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freundii can be reserved for the full cumulative antibiogram.
Whether the infecting organism is E. coli or C. freundii, knowing or
suspecting the causative organism allows for effective utilization
of an antibiogram by matching the organism to the most effective
and safest therapy. Even without identifying the suspected organ-
ism, knowing the Gram-negative susceptibilities to fluoroquino-
lones and third-generation cephalosporins is very relevant to the
front-line prescriber and these should be reported on the abbrevi-
ated antibiogram, while susceptibilities to other antibiotics such as
cefoxitin and tetracyclines may be less useful and can be reported
on the cumulative antibiogram. This would decrease information
overload and provide a simpler version for ease of interpretation.
With the availability of rapid diagnostics such as MALDI-TOF
and nucleic acid amplification tests, a more defined role of the
antibiogram with frontline antimicrobial stewardship clinicians is
warranted. Improved patient outcomes and shorter time to appro-
priate antimicrobials have been observed when rapid diagnostics
are utilized in conjunction with antimicrobial stewardship pro-
grammes (ASP).24,25 In these scenarios, organisms with resistance
markers can be identified prior to susceptibility results. It is in this
intermediary phase between organism identification and suscepti-
bility result where genus and possibly species of organism(s) likely
causing the infection is identified rapidly but susceptibilities are not
yet known. Thus, an antibiogram can be a valuable resource in
honing empirical antimicrobial selection. For example, if a rapid
diagnostic result shows the presence of P. aeruginosa and the
patient is not yet on an antipseudomonal agent, part of the anti-
microbial selection process should include review of antibiogram
susceptibilities to ensure highest probability of susceptibility. ASP
personnel can play a critical role in reviewing the antibiogram in
conjunction with rapid diagnostic results to ensure appropriate
empirical therapy selection. The susceptibility rates from an anti-
biogram are critical information to consider when determining an
appropriate antimicrobial agent for patients with a positive culture.
Susceptibility data derived from an antibiogram should be uti-
lized when generating infectious disease treatment pathways,
including order sets. As order sets and clinical pathways are
typically institution-specific, the use of the antibiogram to guide
antimicrobial selections in each pathway or set will provide the
most evidence-based and data-driven empirical therapies. At a
minimum, the cumulative antibiogram can be utilized for this pur-
pose; however, if an enhanced antibiogram that is stratified by in-
fectious syndrome type is available, a preference for its use should
be considered, as the data obtained can provide more specific
information on susceptibility patterns. Thus, when prescribers util-
ize these treatment pathways or order sets for empirical therapy
selection, their selection will have incorporated the institution’s
susceptibility patterns. The future antibiogram development will
likely coexist with computational models and artificial intelligence
to predict antimicrobial susceptibility. Prediction models are
available to forecast bacterial resistance and therapy selection
based on various factors such as risk factors for site of infection,
community/hospital acquisition, microbiology data, diagnosis
and antimicrobial consumption.26,27 Unfortunately, antimicrobial
resistance models do not take into account social, cultural or
behavioural differences associated with resistance development
or transmission.28,29
Dissemination of the antibiogram to front-line prescribers in
institutions where clinical pathways or order sets are not utilized
may prove to be challenging. Studies noted the feasibility of
a a
Figure 1. An example of a practical abbreviated antibiogram that lists relevant organisms most commonly encountered in typical infections along
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disseminating a pocket antibiogram through electronic means
such as a mobile device application.11,14 Posting the antibiogram
on the institution’s intranet or in physician work rooms or lounges
have also been described.30 Another method to optimize antibio-
gram utilization is through increased accessibility and visualization
such as electronic antibiograms. An electronic antibiogram linked
to the EHR can provide a user interface that allows for selection of
organism, date ranges, infection source and hospital unit, and pro-
vide colour visualization to identify the most susceptible antimicro-
bial options. Hospitals may also link the static and electronic
antibiograms to order sets for easy reference during order entry.31
However, even in the event that antibiograms are readily available
and being utilized, their mere availability alone may not lead to ap-
propriate use. It is prudent to educate front-line prescribers on
how to appropriately utilize the antibiogram in the context of infec-
tious syndromes, as misinterpretation and/or misutilization of the
cumulative antibiogram or its variations when selecting empirical
therapy may lead to suboptimal therapy and outcomes. One such
example of a situation where use of an antibiogram in isolation
may lead to a poor outcome within the context of an infectious
syndrome would be the selection of nitrofurantoin based on high
susceptibility reported for common urinary pathogens for a patient
with pyelonephritis. As nitrofurantoin does not reach adequate
concentrations outside of the bladder, this would be a suboptimal
therapy. This underscores the importance of utilizing the antibio-
gram in conjunction with clinical context and patient-specific fac-
tors, and not simply selecting an agent based on high
susceptibility. Data derived from the antibiogram have limitations
and are only one component to consider when selecting optimal
empirical therapy.
A survey study conducted by Tallman et al.30 examined the use
of the antibiogram by medical residents for selecting empirical
antibiotic therapy in the context of clinical cases. The study authors
found that more than 20% of residents could not accurately select
therapy with an appropriate spectrum of activity in response to the
clinical cases. Even fewer respondents (12%) identified the anti-
biogram as a resource when prescribing empirical antimicrobial
therapy. The majority of residents reported using UpToDate or The
Sanford Guide as primary resources for their selection of empirical
antimicrobial therapy. These resources provide very general spec-
trum of activity information, but lack institution-specific epidemio-
logical data, which along with patient-specific information may
lead to improved empirical therapy selection. Furthermore, 30% of
residents did not feel comfortable using an antibiogram for select-
ing empirical therapy, and only 44% of participants knew where
the antibiogram could be accessed. One suggested area of further
exploration would be evaluation of antibiogram understanding
and utilization among practitioners. Selekman et al.32 evaluated
antimicrobial use in paediatric patients with urinary tract infec-
tions. It was found that only half of the practitioners utilized the
local antibiogram despite having access. The rationale behind the
limited antibiogram use was not a study objective and hence not
explored but provides a direction of potential future research.
Other studies have shown improvement in antimicrobial prescrib-
ing after antimicrobial stewardship and/or antibiogram educa-
tion.33–35 Educating prescribers on antibiogram accessibility and
utilization can provide early trainees guidance and confidence in
their use as well as improvements in antimicrobial prescribing
among practitioners.
It is apparent that various healthcare disciplines such as micro-
biology, pharmacy, medicine and informatics play critical roles in
the design, creation, dissemination, and utilization of antibio-
grams. Many of these disciplines are part of institutional ASP. The
stewardship team should be an integral part of developing valid,
accurate, and utilizable antibiograms, whether they be the cumu-
lative antibiogram or a variation of it. ASP need to ensure optimal
dissemination of the antibiograms to front-line prescribers, edu-
cate on their use and incorporate the data from antibiograms into
institutional treatment pathways and electronic medical record
order sets for various infectious disease syndromes. Additionally,
as institutional ASP are heavily involved in rapid diagnostic device
implementation and use, it further underscores the importance of
antibiogram use in conjunction with the development of clinical
decision support tools and diagnostic platforms.
Conclusions
There exists variability in antibiogram preparation amongst institu-
tions, and the CLSI M39 document should serve as a reference
guide to standardize development. M39 has been updated since
its creation and will continue to be updated to provide new guid-
ance and recommendations for the preparation of cumulative and
enhanced antibiograms. It is imperative that ASP collaborate with
prescribers and the microbiology laboratory to ensure proper dis-
semination, education and utilization of antibiograms. As third-
party surveillance software integrated with institutional EMRs be-
come more common and advanced, it may be possible for these
programmes to be utilized with machine learning to develop anti-
biograms that have real-time access to rapid cumulative antibiotic
profiling data, MIC trends and patient demographics in order to de-
velop sophisticated ‘smart antibiograms’.36 Further understanding
of how to best utilize the cumulative antibiogram and its variations
in the clinical setting, and its effects on patient outcomes, is
warranted.
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